- Home
- PNR vs ASND Comparison
PNR vs ASND Comparison
Compare PNR & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNR | ASND |
|---|---|---|
| Founded | 1966 | 2006 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.7B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PNR | ASND |
|---|---|---|
| Price | $91.27 | $244.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $114.21 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 1.2M | 494.8K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 5.88 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | $96.35 |
| Revenue Next Year | $4.85 | $44.91 |
| P/E Ratio | $22.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.71 | $151.11 |
| 52 Week High | $113.95 | $250.74 |
Technical Indicators
Market Signals| Indicator | PNR | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 60.39 |
| Support Level | $83.60 | $190.49 |
| Resistance Level | $105.10 | $248.60 |
| Average True Range (ATR) | 2.15 | 8.47 |
| MACD | 0.74 | 1.95 |
| Stochastic Oscillator | 86.56 | 83.29 |
Price Performance
Historical ComparisonAbout PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.